Nursing and Health Professions
General Practitioner
100%
General Practice
58%
Cross-Sectional Study
47%
Deprescribing
45%
Proton Pump Inhibitor
45%
Population
42%
Cohort Analysis
37%
Malignant Neoplasm
37%
Statin (Protein)
34%
Predictive Value
34%
Female Genital Tract Cancer
34%
Colorectal Carcinoma
34%
Digestive System Cancer
22%
Bleeding
21%
Socioeconomic Status
17%
Logistic Regression Analysis
16%
Nursing Home
15%
Quality of Life
14%
Drug Therapy
14%
Pelvic Pain
13%
Diagnosis
12%
Rectum Hemorrhage
12%
Biological Therapy
11%
Primary Medical Care
11%
Lung Cancer
11%
Ulcerative Colitis
11%
Lower Urinary Tract Symptom
11%
Urine Incontinence
11%
Health Care Practice
11%
Prophylaxis
11%
Dysphagia
11%
Likert Scale
11%
Enuresis
11%
Social Network
11%
Physician
9%
Comorbidity
8%
Practice Guideline
8%
Abdominal Pain
8%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
7%
Patient Preference
7%
Prevalence
5%
Upper Gastrointestinal Bleeding
5%
Adverse Event
5%
Medicine and Dentistry
Proton-Pump Inhibitor
91%
General Practitioner
66%
Cohort Analysis
49%
Population
37%
General Medicine
35%
Quality of Life
24%
Female Genital Tract Cancer
24%
Irritable Bowel Syndrome
22%
Biological Therapy
22%
Lung Cancer
22%
Colorectal Carcinoma
22%
Malignant Neoplasm
19%
Socioeconomic Status
13%
Cancer Risk
13%
Population Research
13%
Primary Health Care
13%
Diagnosis
13%
Stomach Acid
13%
Observational Study
12%
Endoscopy
12%
Drug Therapy
12%
Peptic Ulcer Bleeding
11%
Upper Gastrointestinal Cancer
11%
Ulcerative Colitis
11%
Gastroesophageal Reflux
11%
Endophthalmitis
11%
Functional Status
11%
Patient with Crohn's Disease
11%
Statin
11%
Cancer Risk Assessment
11%
Randomized Controlled Trial
11%
Infective Endocarditis
11%
Self Rated Health
11%
Systematic Review
11%
Hematogenous Osteomyelitis
11%
Knee Pain
11%
Differential Diagnosis
11%
Side Effect
11%
Rectal Bleeding
10%
Bleeding
9%
Prevalence
9%
Cancer Diagnosis
6%
Disease
6%
Abdominal Pain
5%
Physician
5%
Pharmacology, Toxicology and Pharmaceutical Science
Proton Pump Inhibitor
68%
Statin (Protein)
57%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
32%
Cohort Study
25%
Lung Cancer
22%
Prevalence
17%
Disease
13%
Drug Utilization
13%
Stomach Acid
13%
Comorbidity
12%
Gastroesophageal Reflux
11%
Irritable Colon
11%
Ulcerative Colitis
11%
Crohn's Disease
11%
Side Effect
11%
Colorectal Carcinoma
11%
Cardiovascular Disease
10%
Rectum Hemorrhage
8%
Abdominal Pain
7%
Malignant Neoplasm
6%
